AGP Picks
View all

Cloud-Clone expands skin and mucosal primary cell lineup

Nov. 5, 2026
Cloud-Clone expands skin and mucosal primary cell lineup
By AI, Created 05:17 UTC, Nov 05, 2026, AGP -

Cloud-Clone said it has launched more than 40 skin- and mucosa-focused primary cell products backed by in-house SPF-grade animal facilities and full-chain quality control. The company is positioning the line for wound-healing, inflammation, barrier, fibrosis and drug-screening research.

Why it matters: - Primary cells are the starting point for many skin and mucosal disease studies, so purity, viability and consistency directly affect data quality. - Cloud-Clone is targeting researchers who need ready-to-use cell models for wound repair, inflammation, barrier dysfunction, scar fibrosis, neoplasms and screening workflows. - The company says stronger source control and batch consistency can improve reproducibility in pre-clinical and translational research.

What happened: - Cloud-Clone launched more than 40 primary cell products for skin and mucosal research. - The product line is built around in-house breeding, tissue collection and quality control rather than third-party sourcing. - The release was issued from Houston on Nov. 5, 2026.

The details: - Cloud-Clone operates three in-house SPF-grade animal facilities with a combined area of about 1,000 square meters. - The facilities use standardized IVC housing systems. - Cloud-Clone holds ISO certifications for quality management, environmental management and occupational health and safety management. - The company also has permits for experimental animal production and experimental animal utilization. - The catalog includes more than 560 primary cell types from more than 10 species, including human, mouse, rat, rabbit, dog, cat, pig, sheep and guinea pig. - The skin and mucosal lineup includes epidermal, dermal, skin-appendage, cutaneous and luminal mucosal cell types. - Listed products include adult and neonatal epidermal keratinocytes, oral keratinocytes, lingual epidermal cells, adult/foetal/neonatal dermal fibroblasts, dermal microvascular endothelial cells, subcutaneous preadipocytes, visceral preadipocytes and adipose microvascular endothelial cells. - The cells are available from ready-to-ship stock. - Cloud-Clone says each batch undergoes morphological observation and immunofluorescence identification. - Examples cited include rabbit subcutaneous preadipocytes validated by Oil Red O staining, canine adult epidermal keratinocytes identified with CK18, mouse dermal microvascular endothelial cells identified with Factor VIII, feline adult dermal fibroblasts and rat neonatal dermal fibroblasts identified with fibronectin, and rabbit lingual epidermal cells confirmed with CK18. - The company says the cells support assays for skin physiology, pathological models and new-drug screening.

Between the lines: - The release is as much a credibility statement as a product announcement. - Cloud-Clone is using compliance credentials, in-house sourcing and a published research example to signal that its cells can hold up in demanding experiments. - The mention of a Nature Communications study is meant to show that the cells are being used in high-profile, complex wound-healing research, not only routine lab work.

What's next: - Cloud-Clone says it will keep expanding its primary-cell catalog and refining full-chain quality-control protocols. - The company also plans to work with global research communities on skin disease mechanism studies, therapeutic development and translational biomedicine. - Researchers can request product specifications, batch documentation and technical support through Cloud-Clone’s global support team.

The bottom line: - Cloud-Clone is betting that tighter sourcing controls and broader skin-mucosa cell coverage will make its primary cells more attractive for reproducible research and screening.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Texas Business Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Texas Business Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.